Table 4.

Characteristics of payer adopters and nonadopters of coverage for next-generation tumor sequencing.^*

Payer characteristic	Percentage of adopters, n = 33	Percentage of nonadopters, n = 36	P value
Size, in covered lives
1 000 000 or more	42	39	0.8
Less than 1 000 000	58	61
BlueCross BlueShield member
Yes	36	67	0.02†
No	64	33
Offer Medicare Advantage
Yes	76	69	0.6
No	24	31
Adopted a third-party policy
Yes	45	0	0.0001‡
No	55	100

Sequencing indicates next-generation tumor sequencing.

^*Adopters are payers who adopted positive coverage for sequencing on or before April 1, 2019, for any indication, any sequencing test(s), and any policy stipulation (eg, with or without prior authorization). Nonadopters are payers who had explicit negative coverage for sequencing as of April 1, 2019 (ie, not covering sequencing for any indication or any sequencing test[s]). Size is reported for lives covered by commercial insurance. Offer Medicare Advantage includes payers who service Medicare Advantage plans on behalf of Medicare. Third-party policy is provided by third-party laboratory benefit management company.

^†P < .05.

^‡P < .001.